Tag: Hsv

An estimated 3.8 billion people under 50 have herpes simplex virus type 1 (HSV-1), the main cause of oral herpes [1.8.1]. This raises the question: in the battle against outbreaks, **is lemon balm better than acyclovir?** This article examines the evidence for both treatments.

Globally, an estimated 3.8 billion people under age 50 (64%) have herpes simplex virus type 1 (HSV-1). A common question for those on long-term treatment is: **do you build a tolerance to valacyclovir**, the antiviral medication used to manage it?

While generally considered safe and well-tolerated for prolonged periods, especially in healthy individuals, long-term valacyclovir use can carry potential risks, particularly concerning kidney function. Continuous monitoring by a healthcare provider is advised for those on suppressive therapy to manage and mitigate potential issues.

In a head-to-head Phase 2 clinical trial, the experimental drug pritelivir significantly outperformed the standard-of-care medication valacyclovir for suppressing genital herpes simplex virus (HSV) shedding. This promising new antiviral offers a novel mechanism of action, addressing a critical need for new and more effective **Pritelivir** treatment options, particularly for immunocompromised patients with drug-resistant infections.